Business
Practice ManagementMalpractice ConsultHealth Law & Policy
Media
Case-Based Peer PerspectivesInvestigator Perspectives Medical World NewsPodcastsUrology Medical PerspectivesUTv VideosPeer ExchangeSpecial ReportVirtual Tumor BoardInsightsMedcastPeers & Perspectives
Conferences
Conference ListingConference Previews Conference Recaps
Publications
Urology Times JournalEditorial Advisory BoardUrologists in Cancer CareSupplements and Featured PublicationsClinical Forums Recaps
More
CME/CE
Resources
Begin Your Journey: Tackling BurnoutSponsored MediaLive EventsInteractive ToolsJob BoardPartnersSponsored ResourcesTreatment Landscape Evolutions

Subscribe

  • Business
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Benign Conditions
  • Benign Prostatic Hyperplasia
  • Bladder Cancer
  • Female Urology
  • Genitourinary Cancers
  • Genomic Testing
  • Hormone Therapy
  • Kidney Cancer
  • Kidney Stones
    • Challenging Anatomy
  • Men's Health
  • Next-Generation Imaging
  • OAB and Incontinence
    • Voiding Dysfunction
  • Pediatrics
  • Prostate Cancer
    • Controveries in Urologic Cancer
    • Drug Therapy
  • Sexual Dysfunction
  • UTUC
  • Urologic Surgery
    • Cosmetic Surgery
Spotlight -
Peer Exchange|
Peers and Perspectives|
Case-Based Peer Perspectives|
Urology Times Journal
Advertisement

Gopal N. Gupta, MD

Advertisement

Articles by Gopal N. Gupta, MD

Source: Reprinted from Urology 2019; 126:11 with permission from Elsevier

Bladder Ca biomarkers and BCG: New knowledge of the urinary microbiome

ByRyan A. Dornbier, MD,Petar Bajic, MD,Gopal N. Gupta, MD
August 26th 2019

Study findings have implications for noninvasive markers to predict the course of UCC

Advertisement

Latest Updated Articles

  • Source: Reprinted from Urology 2019; 126:11 with permission from Elsevier
    Bladder Ca biomarkers and BCG: New knowledge of the urinary microbiome

    Published: August 26th 2019 | Updated:



Advertisement
Advertisement

Trending on Urology Times

1

CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC

2

Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC

3

Choosing salvage therapy after prostate cancer focal ablation

4

SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort

5

Mark Tyson, MD shares promising BOND-003 results in papillary NMIBC

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Job Board
  • Terms and Conditions
  • Privacy
  • Do not sell my Personnal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us